Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHH-1V booster immunogenicity and safety study in immunosuppressed adults previously vaccinated against COVID-19
2022-000785-18Phase 3Completed
- Sponsor
- HIPRA
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of PHH-1V in coronavirus disease 2019 (COVID-19), sponsored by HIPRA. Primary endpoint: Neutralization titer against Omicron, Beta, Delta, and other relevant variants at baseline and Day 14. Started Mar 2022; status: completed.
02
Drugs
PHH-1V
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000785-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000785-18.